46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05279417 (ClinicalTrials.gov) | February 2, 2022 | 18/2/2022 | ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA | ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Alone | Rheumatoid Arthritis | Drug: ATI-450 50mg oral tablet BID;Drug: Placebo oral tablet;Drug: Methotrexate;Drug: ATI-450 20mg oral tablet BID | Aclaris Therapeutics, Inc. | NULL | Recruiting | 18 Years | 75 Years | All | 240 | Phase 2 | United States;Czechia;Poland |
| 2 | NCT04247815 (ClinicalTrials.gov) | March 16, 2020 | 16/1/2020 | Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA | A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-controlled Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: ATI-450;Drug: Placebo oral tablet;Drug: Methotrexate | Aclaris Therapeutics, Inc. | NULL | Completed | 18 Years | 70 Years | All | 19 | Phase 2 | United States |